FCM
IBRX icon

Frontier Capital Management’s ImmunityBio IBRX Stock Holding History

Frontier Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-258,134
Closed -$2.96M – 358
2015
Q3 		$2.96M Buy
+258,134
New +$5.63M 0.02% 292

Other funds holding IBRX

WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Frontier Capital Management's IBRX Position: Q4 2015 in Review

Frontier Capital Management sold out of ImmunityBio (IBRX) in Q4 2015, closing a stake of 258,134 shares — an estimated $2.96M sold.

Frontier Capital Management first reported a position in IBRX in Q3 2015 and held it in 1 quarter. The position peaked at $2.96M in Q3 2015. 61 funds tracked by Wall St. Rank hold IBRX as of Q4 2015.

  • Frontier Capital Management reported no remaining ImmunityBio position as of Q4 2015 after selling out during the quarter.
  • Frontier Capital Management sold 258,134 ImmunityBio shares in Q4 2015, an estimated $2.96M.
  • Frontier Capital Management first reported a position in ImmunityBio in Q3 2015 and held it in 1 quarter.
  • Frontier Capital Management's ImmunityBio position peaked at $2.96M in Q3 2015.
  • 61 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2015.

Based on Frontier Capital Management's 13F filing for Q4 2015, filed 27 Jan 2016.